Why the study?
Does multiagent chemotherapy enhance anthracycline cardiotoxicity at cumulative doses below 400 mg/m2 in patients with extremity sarcomas?
Does multiagent chemotherapy enhance anthracycline cardiotoxicity at cumulative doses below 400 mg/m2 in patients with extremity sarcomas?
Multiagent chemotherapy may enhance anthracycline cardiotoxicity, causing severe cardiomyopathy at cumulative doses previously considered safe (<400 mg/m2).
Answers are grounded in this paper and cite their sources.
Raises caution for cardiomyopathy below 400 mg/m2 with multiagent regimens; hypothesis-generating for revised anthracycline thresholds in sarcomas.
Three cases of severe, progressive, and in two cases, fetal cardiomyopathy secondary to anthracycline chemotherapy are reported. All of the patients were receiving multiagent chemotherapy for extremity sarcomas consisting of doxorubicin, high-dose methotrexate, bleomycin, cyclophosphamide, dactinomycin, and cisplatinum at the onset of their congestive heart failure. Cardiomyopathy developed in each patient at cumulative anthracycline doses less than 400 mg/m2. These cases suggest that enhanced cardiotoxicity may occur when anthracyclines are used in combination with other agents such as cyclophosphamide, bleomycin, cisplatinum, and methotrexate and that cumulative anthracycline doses considered to be "safe" may need to be lowered in these circumstances.
No takes yet. Share an insight, caveat, or question.
Raymond G. Watts (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: